Advertisement

Indomethacin acts as an antitumor and anticachexic agent in colon 26-bearing CDF1 mice

  • Mitsuharu Ogino
  • Makoto Hanazono
Original Article

Abstract

Background

This study uses Colon 26-bearing CDF1 mice to assess the pharmacologic actions of indomethacin on tumor growth and cancer cachexia. The effect on tumor growth was evaluated by tumor weight, and the effect on cachexia was screened by changes in body weight and food intake. Additional indices measured included serum levels of immunosuppressive acidic protein and interleukin-6, and prostaglandin E2 content in the tumor tissues.

Methods

Indomethacin (1.0 mg/kg body weight, by oral gavage twice per day) was given to 2 groups of mice, group B (long-term therapy) for 21 days, and group C (short-term therapy) for 7 days. A control group (A) received twice-daily oral gavage of the vehicle alone.

Results

Mean tumor weight was significantly reduced in groups B and C, compared to the control group. Group B had significantly less body weight loss, and true body weight increased significantly in group C mice from day 17, as compared with the control mice. Serum levels of immunosuppressive acidic protein were significantly reduced in both groups B and C, when compared to the nontreated controls. Serum levels of interleukin-6 were also significantly reduced in both groups B and C, compared to the controls. Prostaglandin E2 content in the tumor tissues was significantly lower in both groups B and C than it was in the controls.

Conclusion

Indomethacin was shown to act as an antitumor and anticachexic agent. These findings suggest a potential role for indomethacin as a therapeutic agent for cancer.

Key words

indomethacin prostaglandin E2 interleukin-6 immunosuppressive acidic protein 

References

  1. 1.
    Rappaport RS, Dodge GR. Prostaglandin E inhibits the production of human interleukin 2. J Exp Med 1982;155: 943–948.PubMedCrossRefGoogle Scholar
  2. 2.
    Goodwin JS, Ceuppens J. Regulation of the immune response by prostaglandins. J Clin Immunol 1983;3: 295–315.PubMedCrossRefGoogle Scholar
  3. 3.
    Chouaib S, Chatenoud L, Klatzmann D, Fradelizi D. The mechanism of inhibition of human IL-2 production. II. PGE2 induction of suppressor T lymphocytes. J Immunol 1984;132:1851–1857.PubMedGoogle Scholar
  4. 4.
    Mori H, Hanabayashi T, Yamada Y, Tamaya T. Decrease in interferon-γ production by peripheral blood mononuclear cells in patients with uterine cervical cancer. J Clin Immunol 1990;10:45–51.PubMedCrossRefGoogle Scholar
  5. 5.
    Foldgren P, Sjøgren HO. Influence in vitro on NK and K cell activities by cimetidine and indomethacin with an without simultaneous exposure to interferone. Cancer Immunol Immunother 1985;19:28–34.Google Scholar
  6. 6.
    Lala PK, Parhar RS, Singh P. Indomethacin therapy abrogates the prostaglandin-mediated suppression of natural killer activity in tumor bearing mice and prevents tumor metastasis. Cell Immunol 1986;99:108–118.PubMedCrossRefGoogle Scholar
  7. 7.
    Pedersen BK, Oxholm P, Klarlund K. Characterization of the in vivo and in vitro effects of indomethacin on human natural killer cell activity. Allergy 1986;41:532–536.PubMedGoogle Scholar
  8. 8.
    Baxevanis CN, Recols GJ, Gritzapis AD, Zedousis GVZ, Missitzis I, Papamichail M. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer. Cancer 1993;72:491–501.PubMedCrossRefGoogle Scholar
  9. 9.
    Blitzer A, Huang CC. The effect of indomethacin on the growth of epidermoid carcinoma of the palate in rats. Arch Otolaryngol 1983;109:719–723.PubMedGoogle Scholar
  10. 10.
    Sato M, Narisawa T, Sano T, Takahashi T, Goto A. Growth inhibition of transplantable murine colon adenocarcinoma 38 by indomethacin. J Cancer Res Clin Oncol 1983;106:21–26.PubMedCrossRefGoogle Scholar
  11. 11.
    Bennet A, Carrol MA, Melhish PB, Stamford IF. Treatment of mouse carcinoma in vivo with a prostaglandin E2 analogue and indomethacin. Br J Cancer 1985;52:245–249.Google Scholar
  12. 12.
    Heneghan JB. Inhibition of human colon tumor growth in nude mice by indomethacin. In: Germfree research: microflora control and its application to biomedical science. New York: Alan R. Liss; 1985:315–318.Google Scholar
  13. 13.
    Narisawa T, Henmanek P, Habs M, Schmael D. Reduction of acetoxymethyl-methylnitrosamine-induced large bowel cancer in rats by indomethacin. Tohoku J Exp Med 1984;144:237–243.PubMedCrossRefGoogle Scholar
  14. 14.
    Rao AR, Hussain SP. Modulation of methylcholanthrene-induced carcinogenesis in the uterine cervix of mouse by indomethacin. Cancer Lett 1988;43:15–19.PubMedCrossRefGoogle Scholar
  15. 15.
    Carter CA, Ip MM, Ip C. A comparison of the effects of prostaglandin synthesis inhibitors indomethacin and caprofen of 7, 12-dimethylbenz(a) anthracene-induced mammary tumorigenesis in rats fed different amounts of essential fatty acids. Carcinogenesis 1989;10:1369–1374.PubMedGoogle Scholar
  16. 16.
    Maca RD, Burford JG, Taylor RT. The effects of indomethacin and interleukin-2 on the proliferation of lymphocytes from patients with lung cancer. J Clin Immunol 1985;5:158–165.PubMedCrossRefGoogle Scholar
  17. 17.
    Breau JL, Morere JF, Israel L. Regressions et freinages de croissance de metastases pulmonaires de cancers humain induits par le piroxicam, un inhibiteur de synthese des prostaglandines. Bull Cancer 1989;76:321–328.PubMedGoogle Scholar
  18. 18.
    Hellerstein K, Meydani SN, Meydani M, Wu K, Dinarello CA. Interleukin-1-induced anorexia in the rat—influence of prostaglandins. J Clin Invest 1989;84:228–235.PubMedGoogle Scholar
  19. 19.
    Sandstrøm R, Gelin J, Lundholm K. The effect of indomethacin on food and water intake, motor activity and survival in tumor-bearing rats. Eur J Cancer 1990;26:811–814.PubMedCrossRefGoogle Scholar
  20. 20.
    Gelin J, Andersson C, Lundholm K. Effects of indomethacin, cytokines, and cyclosporin A on tumor growth and the subsequent development of cancer cachexia. Cancer Res 1991;51:880–885.PubMedGoogle Scholar
  21. 21.
    Shibata Y, Tamura K, Ishida N. In vivo analysis of the suppressive effects of immunosuppressive acidic protein, a type of α1-acid glycoprotein, in connection with its high level in tumor-bearing mice. Cancer Res 1983; 43:2889–2896.PubMedGoogle Scholar
  22. 22.
    Strassmann G, Fong M, Kenney JS, Jacob CO. Evidence for the involvement of interleukin-6 in experimental cancer cachexia. J Clin Invest 1992;89:1681–1684.PubMedCrossRefGoogle Scholar
  23. 23.
    Strassmann G, Jacob Co, Evans R, Beall D, Fong M. Mechanisms of experimental cancer cachexia and its relevance to IL-6-mediated cancer cachexia. J Immunol 1992; 148:3674–3678.PubMedGoogle Scholar
  24. 24.
    Ogino M, Abe Y, Okahara T, Jimbo T. Comparison of plasma prostanoid levels in the human cord artery in normal and fetal distressed deliveries. Endocrinol Jpn 1986; 33(1):75–80.PubMedGoogle Scholar
  25. 25.
    Lowry OH, Rosenbrough NH, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265–275.PubMedGoogle Scholar
  26. 26.
    Mossmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 1984;65:55–63.CrossRefGoogle Scholar
  27. 27.
    Favalli C, Garaci E, Etheredge E, Santoro MG, Jaffe BM. Influence of PGE on the immune response in melanoma-bearing mice. J Immunol 1980;125:897–902.PubMedGoogle Scholar
  28. 28.
    Hofer D, Dubitsky AM, Reilly P, Santoro MG, Jaffe BM. The interactions between indomethacin and cytotoxic drugs in mice bearing B-16 melanomas. Prostaglandins 1980;20:1033–1038.PubMedCrossRefGoogle Scholar
  29. 29.
    Feldmann JM, Hilf R. Failure of indomethacin to inhibit growth of the R3230 AC mammary tumor in rats. J Natl Cancer Inst 1985;75:751–756.Google Scholar
  30. 30.
    30.Fulton AM. In vivo effects of indomethacin on the growth of murine mammary tumors. Cancer Res 1984;44:2416–2420.PubMedGoogle Scholar
  31. 31.
    Maca RD. Inhibition of the growth of Lewis lung carcinoma by indomethacin in conventional, nude, and beige mice. J Biol Response Mod 1988;7:568–580.PubMedGoogle Scholar
  32. 32.
    Norton JA, Peacock JL, Morrison SD. Cancer cachexia. Crit Rev Oncol Hematol 1987;7:289–327.PubMedGoogle Scholar
  33. 33.
    DeWys WD, Begg C, Lavin PT. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 1980;69:491–497.PubMedCrossRefGoogle Scholar
  34. 34.
    DeWys WD, Begg C, Band P, Tormey D. The impact of malnutrition on treatment results in breast cancer. Cancer Treat Rep 1981;65 (suppl 5):87–91.PubMedGoogle Scholar
  35. 35.
    McCarthy DO, Kluger M, Vander A. Suppression of food intake during infection: is interleukin-1 involved. Am J Nutr 1985;42:1179–1182.Google Scholar
  36. 36.
    Stovroff MC, Fraker DL, Swedenborg JA, Norton JA. Cachectin/tumor necrosis factor: a possible mediator of cancer anorexia in the rat. Cancer Res 1988;48:4567–4572.PubMedGoogle Scholar
  37. 37.
    Iseki H, Kajimura N, Ohue C, Tanaka R, Akiyama Y, Yamaguchi K. Cytokine production in five tumor cell lines with activity to induce cancer cachexia syndrome in nude mice. Jpn J Cancer Res 1995;86:562–567.PubMedGoogle Scholar
  38. 38.
    Ouchi KF, Tamura S, Mori K, Tanaka Y, Ishitsuka H. Establishment and characterization of cachexia-inducing and non-inducing clones of murine Colon 26 carcinoma. Int J Cancer 1995;61:522–528.Google Scholar
  39. 39.
    Smith KL, Tisdale MJ. A mechanism of muscle protein degradation in cancer cachexia. Br J Cancer 1993;68:314–318.PubMedGoogle Scholar
  40. 40.
    Soda K, Kawakami M, Kashii A, Miyata M. Characterization of mice bearing subclone of Colon 26 adenocarcinoma disqualifies interleukin-6 as the sole inducer of cachexia. Jpn J Cancer Res 1994;85:1124–1130.PubMedGoogle Scholar

Copyright information

© JSCO/CLJ 1998

Authors and Affiliations

  • Mitsuharu Ogino
    • 1
  • Makoto Hanazono
    • 2
  1. 1.Department of Obstetrics and GynecologyTeikyo University School of MedicineIchiharaJapan
  2. 2.The Clinical Research CenterTeikyo University School of MedicineIchiharaJapan

Personalised recommendations